Urinary estrogen metabolites and breast cancer: Differential pattern of risk found with pre- versus post-treatment collection

Steroids

Volumn 68, Issue 1, 2003, Pages 65-72

  Fowke, Jay H ^a   Qi, Dai ^a   Bradlow, H Leon ^b   Shu, Xiao Ou ^a   Gao, Yu Tang ^c   Cheng, Jin Rong ^c   Jin, Fan ^c   Zheng, Wei ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b HACKENSACK UNIVERSITY MEDICAL CENTER   (United States)

^c SHANGHAI CANCER INSTITUTE   (China)

Author keywords

Bias; Biomarker; Breast cancer; Diet; Estrogen metabolism; Urine

Indexed keywords

16ALPHA HYDROXYESTRONE; 2 HYDROXYESTRONE; 16 HYDROXYESTRONE; 16-HYDROXYESTRONE; ESTROGEN; ESTRONE DERIVATIVE;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CARCINOMA; CANCER SURGERY; CANCER THERAPY; CHINESE; CONTROLLED STUDY; DIETARY INTAKE; DISEASE MARKER; ESTROGEN URINE LEVEL; FEMALE; HUMAN; LOGISTIC REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; POSTMENOPAUSE; PREMENSTRUAL SYNDROME; URINALYSIS; BREAST TUMOR; CASE CONTROL STUDY; CHINA; METABOLISM; MIDDLE AGED; PREMENOPAUSE; RISK; RISK FACTOR; URINE;

JOINVILLEA ASCENDENS;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; CHINA; ESTROGENS; FEMALE; HUMANS; HYDROXYESTRONES; MIDDLE AGED; ODDS RATIO; POSTMENOPAUSE; PREMENOPAUSE; RISK FACTORS;

EID: 0037211257     PISSN: 0039128X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-128X(02)00116-2     Document Type: Article

References (39)

1. Hankinson S.E., Willett W.C., Manson J.E., Colditz G.A., Hunter D.J., Spiegelman D.et al. Plasma sex steroid hormone levels and risk of breast cancer in post-menopausal women. J. Natl. Cancer Inst. 90:1998;1292-1299.
2. Osborne M.P., Bradlow H.L., Wong G.Y., Telang N.T. Upregulation of estradiol 16 alpha-hydroxylation in human breast tissue: a potential biomarker of breast cancer. J. Natl. Cancer Inst. 85:1993;1917-1920.
3. Bradlow H.L., Hershcopf R.J., Martucci C.P., Fishman J. Estradiol 16α-hydroxylation in the mouse correlates with mammary tumor incidence and presence of murine mammary tumor virus: a possible model for hormonal etiology of breast cancer in humans. Proc. Natl. Acad. Sci. U.S.A. 82:1985;6295-6299.
4. Fotsis T., Zhang Y., Pepper M.S., Adlercreutz H., Montesana R., Nawroth P.P.et al. The endogenous estrogen metabolite 2-methoxyestradiol inhibits angiogenesis and suppresses tumor growth. Nature. 368:1994;237-239.
5. Zhu B.T., Conney A.H. Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis. 19:1998;1-27.
6. Schumacher G., Neuhaus P. The physiological estrogen metabolite 2-methoxyestradiol reduces tumor growth and induces apoptosis in human solid tumors. J. Cancer Res. Clin. Oncol. 127:2001;405-410.
7. Zheng W., Dunning L., Jin F., Holtzman J. Correspondence re: G.C. Kabat et al., urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidem. Biomark. Prev. 7:1998;85-86.
8. Kabat G.C., Chang C.J., Sparano J.A., Sepkovic D.W., Hu X.-P., Khalil A.et al. Urinary estrogen metabolites and breast cancer: a case-control study. Cancer Epidem. Biomark. Prev. 6:1997;505-509.
9. Ho G.H., Luo X.W., Ji C.Y., Foo S.C., Ng E.H. Urinary 2/16-hydroxyestrone ratio: correlation with serum insulin-like growth factor binding protein-3 and a potential biomarker of breast cancer. Ann. Acad. Med. Singapore. 27:1998;294-299.
10. Meilahn E., DeStavola B., Allen D., Fentim I., Bradlow H., Sepkovic D.et al. Do urinary oestrogen metabolites predict breast cancer? Guernsey III cohort follow-up. Br. J. Can. 78:1998;1250-1255.
11. Muti P., Bradlow H.L., Micheli A., Krogh V., Freudenheim J.L., Schünemann H.J.et al. Estrogen metabolism and risk of breast cancer: a prospective study of the 2:16alpha-hydroxyestrone ratio in pre-menopausal and post-menopausal women. Epidemiology. 11:2000;635-640.
12. Schneider J., Kinne D., Fracchia A., Pierce V., Anderson K.E., Bradlow H.L.et al. Abnormal oxidative metabolism of estradiol in women with breast cancer. Proc. Natl. Acad. Sci. USA. 79:1982;3047-3051.
13. Ursin G., London S., Stanczyk F.Z., Gentzchein E., Paganini-Hill A., Ross R.K.et al. Urinary 2-hydroxyestrone/16α-hydroxyestrone ratio and risk of breast cancer in post-menopausal women. J. Natl. Cancer Inst. 91:1999;1067-1072.
14. Demark-Wahnefried W., Rimer B.K., Winer E.P. Weight gain in women diagnosed with breast cancer. J. Am. Diet. Assoc. 97:1997;519-526.
15. Rock C., McEligot A.J., Flatt S.W., Sobo E.J., Wilfley D.E., Jones V.E.et al. Eating pathology and obesity in women at risk for breast cancer recurrence. Int. J. Eat. Disord. 27:2000;172-179.
16. Demark-Wahnefried W., Hars V., Conaway M.R., Havlin K., Rimer B.K., McElveen G.et al. Reduced rates of metabolism and decreased physical activity in breast cancer patients receiving adjuvant chemotherapy. Am. J. Clin. Nutr. 65:1997;1495-1501.
17. Rock C., Flatt S.W., Newman V., Caan B.J., Haan M.N., Stefanick M.L.et al. Factors associated with weight gain in women after diagnosis of breast cancer. J. Am. Diet. Assoc. 99:1999;1212-1218.
18. Holm L.E., Nordevang E., Hjalmar M.L., Lidbrink E., Callmer E., Nilsson B. Treatment failure and dietary habits in women with breast cancer. J. Natl. Cancer Inst. 85:1993;32-36.
19. Zheng W., Jin F., Dunning L.A., Shu X.-O., Dai Q., Wen W.-Q.et al. Epidemiological study of urinary 6β-hydroxycortisol to cortisol ratios and breast cancer risk. Cancer Epidem. Biomark. Prev. 10:2001;237-242.
20. Chen Z., Zheng W., Dunning L., Anderson K., Parrish R., Holzman J.L. Within-person variability of the ratios of urinary 2-hydroxyestrone to 16alpha-hydroxyestrone in Caucasian women. Steroids. 64:1999;856-859.
21. Westerlind K.C., Gibson K.J., Wolfe P. The effect of diurnal and menstrual cyclicity and menopausal status on estrogen metabolites: implications for disease-risk assessment. Steroids. 64:1999;233-243.
22. Chinese Academy of Medical Sciences. Food composition tables. Beijing: People's Health Publishing House; 1991.
23. Bradlow H.L., Sepkovic D.W., Klug T., Osborne M.P. Application of an improved ELISA assay to the analysis of urinary estrogen metabolites. Steroids. 63:1998;406-413.
24. Castagnetta L.A.M., Carruba G. Re: urinary 2-hydroxyestrone/16alpha-hydroxyestrone ratio and risk of breast cancer in post-menopausal women. J. Natl. Cancer Inst. 91:1999;1893.
25. Michaud D.S., Manson J.E., Spiegelman D., Barbieri R.L., Sepkovic D.W., Bradlow H.L.et al. Reproducibility of plasma and urinary sex hormone levels in pre-menopausal women over a 1-year period. Cancer Epidem. Biomark. Prev. 8:1999;1059-1064.
26. Michnovicz J.J., Hershcopf R.J., Naganuma H., Bradlow H.L., Fishman J. Increased 2-hydroxylation of estradiol as a possible mechanism for the anti-estrogenic effect of cigarette smoking. NEJM. 315:1986;1305-1309.
27. Xu X., Duncan A., Merz B.E., Kurzer M.S. Effects of soy isoflavones on estrogen and phytoestrogen metabolism in pre-menopausal women. Cancer Epidem. Biomark. Prev. 7:1998;1101-1108.
28. Fowke J.H., Longcope C., Hebert J.R. Brassica vegetable consumption shifts estrogen metabolism in healthy post-menopausal women. Cancer Epidem. Biomark. Prev. 9:2000;773-779.
29. Kall M.A., Vang O., Clausen J. Effects of dietary broccoli on human in vivo drug metabolizing enzymes: evaluation of caffeine, estrone, and chlorzoxazone. Carcinogenesis. 17:1996;793-799.
30. Bradlow H.L., Telang N.T., Sepkov D.W., Osborne M.P. 2-Hydroxyestrone: the 'good' estrogen. J. Endocrinol. 150:1996;S256-S265.
31. Huang Z., Guengerich F.P., Kaminsky L.S. 16 Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis. 19:1998;867-872.
32. Cavalieri E.L., Stack D.E., Devanesan P.D., Todorovic R., Dwivedy S., Higginbotham S.L.et al. Molecular origin of cancer: catechol estrogen-3,4 quinones as endogenous tumor initiators. Proc. Natl. Acad. Sci. 94:1997;10937-10942.
33. Li J.J., Li S.A., Oberley T.D., Parsons J.A. Carcinogenic activities of various steroidal and nonsteroidal estrogens in the hamster kidney: relation to hormonal activity and cell proliferation. Cancer Res. 55:1995;4347-4351.
34. Liehr J.G. Hormone-associated cancer: mechanistic similarities between human breast cancer and estrogen-induced kidney carcinogenesis in hamsters. Environ. Health Perspect. 105:1997;565-569.
35. McFadyen M.C.E., Breeman S., Payne S., Stirk C., Miller I.D., Melvin W.T.et al. Immunohistochemical localization of cytochrome P450 CYP1B1 in breast cancer with monoclonal antibodies specific for CYP1B1. J. Histochem. Cytochem. 47:1999;1457-1464.
36. Zheng W., Xie D.W., Jin F., Cheng J.R., Dai Q., Wen W.Q.et al. Genetic polymorphism of cytochrome P450-1B1 and risk of breast cancer. Cancer Epidem. Biomark. Prev. 9:2000;147-150.
37. Bailey L.R., Roodi N., Dupont W.D., Parl F.F. Association of cytochrome P450 1B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res. 58:1998;5038-5041.
38. DeCrée C., Van Kranenburg G., Geuten P., Fujimori Y., Keizer H.A. 4-Hydroxycatecholestrogen metabolism responses to exercise and training: possible implications for menstrual cycle irregularities and breast cancer. Fertil. Steril. 67:1997;505-516.
39. DeCrée C., Ball P., Seidlitz B., Van Kranenburg G., Geurten P., Keizer H.A. Plasma 2-hydroxycatecholestrogen responses to acute submaximal and maximal exercise in untrained women. J. Appl. Physiol. 82:1997;364-370.